Method for PR-39 peptide mediated selective inhibition of...

Details Method for PR-39 peptide mediated selective inhibition of... Method for PR-39 peptide mediated selective inhibition of...

2007-04-10

2007-04-10

Lankford, Jr., Leon B. (Department: 1651)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S015800, C435S001100, C435S004000, C435S325000

Reexamination Certificate

active

10391155

ABSTRACT:
The present invention provides both a method and means for regulating IκBα degradation, NFκB activity, and NFκB-dependent gene expression within living cells, tissues, and organs in-situ. The selective regulation is performed using native PR-39 peptide or one of its shorter-length homologs, for interaction with such IκBα and proteasomes as are present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with IκBα is a selective alteration in the intracellular proteolytic activity of proteasomes, which in turn, causes a reduction of IκBα, a decrease of NFκB activity, and a down-regulation of NFκB-dependent gene expression.

REFERENCES:
Anderson. Nature vol. 392. 1998. pp. 25-30.
Verma et al. Nature vol. 389. 1997. pp. 239-242.

Affiliated with

Also associated with

Rating

Method for PR-39 peptide mediated selective inhibition of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for PR-39 peptide mediated selective inhibition of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for PR-39 peptide mediated selective inhibition of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3776476